Axiom MRC has updated all it's market research reports with the Economic Impact Analysis of COVID19 Pandemic on the market. Our team of analyst are following Comprehensive Three Dimensional (3D) Research Methodology along with large number primary interviews with key industry participants to bring insightful market reports to meet the current market requirements.
Molecular Cytogenetics encompasses all aspects of chromosome biology and the application of molecular cytogenetic techniques in all areas of biology and medicine, including structural and functional organization of the chromosome and nucleus, genome variation, expression and evolution, chromosome abnormalities and genomic variations in medical genetics and tumor genetics. The application of new multicolour karyotyping techniques has allowed the complete dissection of complex chromosome rearrangements and provides the prospect of identifying new recurrent chromosome rearrangements. Recent developments in comparative genomic hybridization to DNA microarrays provide the promise of high resolution and automated screening for chromosomal imbalances. Rather than replacing conventional cytogenetics, however, these techniques have extended the range of cytogenetic analyses when applied in a complementary fashion.
Rising healthcare expenditure, technological advancements and growing prevalence of cancer and genetic disorders are some major factors driving the growth of the molecular cytogenetics systems market. Additionally, rising focus toward the targeted therapy for cancer treatment has also impacted the growth of the molecular cytogenetics systems market globally. On the other hand, factors such as high cost of molecular cytogenetics instruments are hampering the growth of the market.
The molecular cytogenetics market is segmented by product, technology, application, end user and geography.
On the basis of product, the molecular cytogenetics market is classified into kits & reagents, instruments, consumables, data management software and services. The kits & reagents segment is further classified into testing kits, probes, fluorescent affinity reagents and other kits & reagents. The kits & reagents segment accounted for the largest market share, owing to the growing incidence of genetic disorders and cancer is a main market driver in this segment.
Based on technology, the molecular cytogenetics market is segmented comparative genomic hybridization, fluorescence in situ hybridization (FISH), immunohistochemistry, karyotyping, and other techniques. The comparative genomic hybridization segment is classified into array-based comparative genomic hybridization and Standard comparative genomic hybridization. Likewise, karyotyping segment is bifurcated into spectral karyotyping and virtual karyotyping. FISH and Comparative Genomic Hybridization (CGH) are among the most known cytogenetic techniques as they offer thorough information about cancer-related molecular signatures.
On the basis of application, the molecular cytogenetics market is segmented into genetic disorders, cancer, personalized medicine and other applications. Personalized treatment options are known as the two most vital strategies for achieving improved treatment outcomes. With a shift to personalized medicine, the usage of molecular cytogenetic techniques is projected to grow efficiently throughout the projection period.
By end user, the molecular cytogenetics market is bifurcated into clinical & research laboratories, academic research institutes, pharmaceutical and biotechnology companies and other end users. The clinical & research laboratories segment dominated the market, due to rising application of cytogenetic techniques in clinical diagnosis and advancement in ongoing research.
The molecular cytogenetics market report is studied across the key countries of North America, Europe, Asia Pacific and Rest of the World. North America dominates the market for molecular cytogenetics, accounting for the highest market value in 2018, owing to the rising aged population, high incidence of genetic disorders and cancer and high healthcare expenditure. Whereas, Asia Pacific is expected to witness the fastest growth rate during the forecast period.
Some key players of this market includes ABBott Laboratories, Inc., Agilent Technologies, Inc., Applied Spectral Imaging, Bio-Rad Laboratories, Inc., Danaher Corporation, Illumina, Inc., Oxford Gene Technology (OGT), Perkinelmer, Inc., F. Hoffmann-LA Roche Ltd., Thermo Fisher Scientific Inc., CytoTest Inc., Weill Cornell Medicine, UCLA Health - UCLA Pathology and Laboratory Medicines, OHSU School of Medicine-Molecular and Medical Genetics, Integrated Systems Engineering S.r.l., WiCell Research Institute, Inc., Virtual Scientific, UW Cytogenetic Services, Genesis Laboratories Inc., Calgary Laboratory Services, Neogenomics, ARUP Laboratories, South West Thames Regional Genetics Service., F. Hoffmann-La Roche Ltd., SciGene Corporation, LEICA BIOSYSTEMS and Life Technologies Corporation. New product launches, research and development and mergers & acquisitions are the key strategies adopted by market players to ensure their growth in the market.
July 2016: Thermo Fisher Scientific and HEALTH BioMed (China) collaborated to support HBM’s development of molecular diagnostic kits for infectious diseases and pharmacogenomics screening which will serve the Chinese market.
January 2016: Thermo Fisher Scientific, Inc. acquired Affymetrix (U.S.). This acquisition strengthened Thermo Fisher Scientific's leadership into bioscience business and create new market opportunities in genetic analysis.
February 2015: Roche announced the acquisition of Signature Diagnostics AG (Signature), a privately held company based in Potsdam, Germany. Signature is a translational oncology and genomics company that develops large blood plasma and tissue biobanks in multiple cancers, including colorectal and lung, which are constructed from multicenter prospective clinical studies.
The molecular cytogenetics market is segmented by product, technology, application, end user and geography. On the basis of product, the molecular cytogenetics market is classified into kits & reagents, instruments, consumables, data management software and services. The kits & reagents segment is further classified into testing kits, probes, fluorescent affinity reagents and other kits & reagents. The kits & reagents segment accounted for the largest market share, owing to the growing incidence of genetic disorders and cancer is a main market driver in this segment.
Based on technology, the molecular cytogenetics market is segmented comparative genomic hybridization, fluorescence in situ hybridization (FISH), immunohistochemistry, karyotyping, and other techniques. The comparative genomic hybridization segment is classified into array-based comparative genomic hybridization and Standard comparative genomic hybridization. Likewise, karyotyping segment is bifurcated into spectral karyotyping and virtual karyotyping. FISH and Comparative Genomic Hybridization (CGH) are among the most known cytogenetic techniques as they offer thorough information about cancer-related molecular signatures.
On the basis of application, the molecular cytogenetics market is segmented into genetic disorders, cancer, personalized medicine and other applications. Personalized treatment options are known as the two most vital strategies for achieving improved treatment outcomes. With a shift to personalized medicine, the usage of molecular cytogenetic techniques is projected to grow efficiently throughout the projection period.
By end user, the molecular cytogenetics market is bifurcated into clinical & research laboratories, academic research institutes, pharmaceutical and biotechnology companies and other end users. The clinical & research laboratories segment dominated the market, due to rising application of cytogenetic techniques in clinical diagnosis and advancement in ongoing research.
The molecular cytogenetics market report is studied across the key countries of North America, Europe, Asia Pacific and Rest of the World. North America dominates the market for molecular cytogenetics, accounting for the highest market value in 2018, owing to the rising aged population, high incidence of genetic disorders and cancer and high healthcare expenditure. Whereas, Asia Pacific is expected to witness the fastest growth rate during the forecast period.
Why to buy this report:
